BioStem Technologies, Inc.
NASDAQ:BSEMBiotechnology
-$0.21 today
- Market cap
- $52.14M
- Beta
- 0.26
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$1.63
Volume 0.09M
Average 0.07M
BSEM Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
BioStem Technologies, Inc.NASDAQ: BSEM
Accounts Payables · Q2 FY2026 · quarter ended Jun 2026
Accounts payables grows, but more slowly than its trailing trend
Q2 FY2026 accounts payables of $865.63K rose 110.8% year over year, behind the +237.1% change in trailing-twelve-month accounts payables. Sequentially, it fell 78.6% from the prior quarter. Over 3 fiscal years it compounded at +168.6% a year.
Context
- Accounts payables amounted to 3.1% of revenue in FY2025, up 1.7 pp from a year earlier.
- Accounts payables increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +110.8% toward the trailing-twelve-month pace of +237.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- (1.5M) USD
- Year-over-year change
- -133.8%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (1.5M) | -133.8% |
| FY2024 | 2024-12-31 | 4.42M | +437.9% |
| FY2023 | 2023-12-31 | 821.57K | +1165.0% |
| FY2022 | 2022-12-31 | (77.14K) | -295.8% |
| FY2021 | 2021-12-31 | (19.49K) | — |
Accounts Payables vs competitors
How BSEM compares with its peers on the latest reported figures
No competitor Accounts Payables figures are available to compare.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (1.41M) | (7.11M) | (8.48M) | 31.88M | (6.58M) |
| Depreciation & Amortization | 283.79K | 243.42K | 395.32K | 293.22K | 381.02K |
| Deferred Income Tax | (689.36K) | 0 | 0 | 0 | 3.99M |
| Stock-Based Compensation | 403.02K | 4.9M | 6.67M | 0 | 0 |
| Change in Working Capital | 515.9K | 7.59K | (3.54M) | (12.01M) | (3.98M) |
| Accounts Receivables | (288.25K) | 262.93K | (11.33M) | (93.78M) | 4.43M |
| Inventory | 209.35K | (135.18K) | (263.45K) | (1.17M) | (1.05M) |
| Accounts Payables | (19.49K) | (77.14K) | 821.57K | 4.42M | (1.5M) |
| Other Working Capital | 614.3K | (43.03K) | 8.06M | 78.52M | (5.86M) |
| Other Non-Cash Items | 788.99K | 322.58K | 1.46M | 4.31M | 16.12M |
| Operating Cash Flow | (109.44K) | (1.64M) | (3.5M) | 24.48M | 9.94M |
| Capital Expenditures | (42.85K) | (469.48K) | (105.33K) | (426.57K) | (3.35M) |
| Acquisitions (Net) | 35K | 0 | (105K) | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | (1.25M) | 1.25M |
| Investing Cash Flow | (7.85K) | (469.48K) | (210.33K) | (1.68M) | (2.1M) |
| Debt Repayment | 232.42K | 547.71K | 797.06K | (849.4K) | (1.17M) |
| Common Stock Issued | 125K | 50K | 2.38M | 642.62K | 48.33K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (391.79K) | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 357.42K | 597.71K | 3.18M | (206.78K) | (1.12M) |
| Effect of Forex Changes | 0 | 1.97M | 0 | 0 | 0 |
| Net Change in Cash | 240.13K | 431.8K | (532.73K) | 22.59M | 6.72M |
| Free Cash Flow | (152.29K) | (2.11M) | (3.6M) | 24.05M | 6.59M |
BioStem Technologies, Inc.
NASDAQ:BSEM
Intrinsic Alpha fair value
Locked
Current Price
$3.07
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.